PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX01): An open label, non-comparative phase 1/2 dose escalation and expansion trial.

Frédéric DumontVahan KepenekianChristophe PassotAnne-Cécile Ezanno-ManasterskiMarc PocardJean-Luc RaoulBénédicte LelièvreSandrine HiretHélène SenellartFrancois PeinJudith RaimbourgLoic CampionEmilie ThibaudeauJulie PaulOlivier Glehennull null

Published in: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2024)

In patients with advanced and refractory peritoneal metastasis, PFS of 6.1 months is encouraging. A prospective randomized phase II study is required.

Keyphrases

phase ii study
open label
phase iii
phase ii
study protocol
clinical trial
locally advanced
placebo controlled
randomized controlled trial
squamous cell carcinoma
radiation therapy